Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case

Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case–control study

Published:2020-02-14 Issue:4 Volume:31 Page:321-332
ISSN:0957-5243
Container-title:Cancer Causes & Control
language:en
Short-container-title:Cancer Causes Control

Author:

Shen Yi,Risch Harvey,Lu Lingeng,Ma Xiaomei,Irwin Melinda L.,Lim Joseph K.,Taddei Tamar,Pawlish Karen,Stroup Antoinette,Brown Robert,Wang Zhanwei,Jia Wei,Wong Linda,Mayne Susan T.,Yu Herbert^ORCID

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10552-020-01277-1.pdf

Reference50 articles.

1. Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

2. Pisani P, Bray F, Parkin DM (2002) Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97(1):72–81

3. Ma X, Yu H (2006) Global burden of cancer. Yale J Biol Med 79(3–4):85–94

4. Torre LA et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108

5. McGlynn KA, London WT (2005) Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 19(1):3–23

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights in Molecular Therapies for Hepatocellular Carcinoma;Cancers;2024-05-10

2. Detection of hepatocellular carcinoma methylation markers in salivary DNA;Bioscience Reports;2024-03

3. Trends in liver cancer mortality in China from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019;BMJ Open;2023-12

4. Interaction between hepatitis B, hepatitis C and smoking in the development of hepatocellular carcinoma: a systematic review and meta-analysis;Journal of Public Health;2023-11-02

5. Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition;Cancer Cell International;2023-09-16